Richard /Ca/ Murray - Feb 1, 2022 Form 4 Insider Report for Jounce Therapeutics, Inc. (JNCE)

Role
CEO and President, Director
Signature
/s/ Kim C. Drapkin, Attorney-in-Fact
Stock symbol
JNCE
Transactions as of
Feb 1, 2022
Transactions value $
$0
Form type
4
Date filed
2/3/2022, 06:37 PM
Previous filing
Jan 11, 2022
Next filing
Jan 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNCE Common Stock Award $0 +87.5K +47.15% $0.00 273K Feb 1, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNCE Stock Option (Right to Buy) Award $0 +175K $0.00 175K Feb 1, 2022 Common Stock 175K $7.56 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest quarterly in 16 equal installments following January 1, 2022.